This bill, known as the Hemp Enforcement, Modernization, and Protection Act, aims to establish a comprehensive regulatory framework for cannabinoid hemp products by amending the Federal Food, Drug, and Cosmetic Act. Its primary purpose is to ensure the safety, quality, and proper labeling of these products, bringing them under federal oversight similar to other regulated consumer goods. The legislation introduces new definitions and creates a dedicated chapter within the Act for cannabinoid hemp product regulation. The bill defines "cannabinoid" broadly, encompassing various chemical subclasses found in or derived from Cannabis sativa L., including both naturally occurring and synthetic forms. A "cannabinoid hemp product" is any article containing one or more listed cannabinoids intended for human or animal use, excluding approved drugs, biological products, or certain food additives. Crucially, it defines a "prohibited cannabinoid product" as one exceeding specified intoxicating cannabinoid content thresholds, containing certain synthetic cannabinoids, or intended for food-producing animals, among other criteria. The legislation categorizes cannabinoid hemp products into oral, inhalable, and topical forms, each with specific standards. Oral products face limits on total and individual cannabinoid content per serving and package, with requirements for multi-serving packaging and liquid containers. Inhalable products have stringent rules regarding sourcing, ingredients (prohibiting most added terpenes or flavoring agents), and manufacturing solvents, and must generally be sold in prefilled, nonrefillable cartridges. All cannabinoid hemp products are subject to extensive labeling requirements, including manufacturer information, quantity, cannabinoid content (including total intoxicating content), allergen disclaimers, risk warnings, and a QR code linking to a certificate of analysis. Labels must also disclaim FDA approval for safety or effectiveness and state that the product is not a food or dietary supplement. Packaging must be child-safe and tamper-evident, and must avoid marketing features that appeal to individuals under 21. The bill mandates that all cannabinoid hemp products adhere to uniform manufacturing and testing requirements established by the Secretary, covering specifications for components, contaminants, and cannabinoid content. Facilities involved in manufacturing, processing, or importing these products must register with the Secretary and list their products, with provisions for biennial renewal and inspection. Foreign facilities are also subject to inspection, and refusal to permit inspection can lead to product refusal for import. A significant provision grants the Secretary mandatory recall authority for products deemed adulterated or misbranded with a reasonable probability of causing serious adverse health consequences or death. If a responsible person fails to voluntarily recall such a product, the Secretary can issue an order to cease distribution or recall. The bill also establishes a Cannabinoid Hemp Products Advisory Committee to provide expert advice on content limits and other regulatory matters. Enforcement provisions include classifying the introduction or receipt of prohibited cannabinoid products, sales to individuals under 21, and failure to adhere to manufacturing standards as prohibited acts. Violations of these provisions carry enhanced criminal penalties, including imprisonment and fines. The Secretary is also directed to establish specific thresholds for total and intoxicating cannabinoid content, with default limits provided if the final rule is not issued within three years, such as 5 milligrams of intoxicating cannabinoid content per serving and 30 milligrams per package for oral products.